Effect of spironolactone use in pulmonary arterial hypertension – analysis from pivotal trial databases
Spironolactone, a common diuretic used in the treatment of pulmonary arterial hypertension (PAH), improves cardiopulmonary hemodynamics by attenuating the adverse effects of hyperaldosteronism on endothelin type-B receptor function within pulmonary endothelial cells. Spironolactone has demonstrated...
Guardado en:
Autores principales: | Zeenat Safdar, Eunah Cho |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/feae43b6f1f849f2a33c67f2dc06260f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Liver abnormalities in pulmonary arterial hypertension
por: Nils P. Nickel, et al.
Publicado: (2021) -
Systemic arterial properties in pulmonary hypertension
por: Randi Goodman, et al.
Publicado: (2021) -
Global trends in chronic thromboembolic pulmonary hypertension clinical trials and dissemination of results
por: Micheal C. McInnis, et al.
Publicado: (2021) -
PeakPCO combined with FEV1/FVC predicts vasodilator-responsive patients with idiopathic pulmonary arterial hypertension
por: Ci-Jun Luo, et al.
Publicado: (2021) -
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
por: Robert P. Frantz, et al.
Publicado: (2021)